Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been assigned a consensus rating of “Hold” from the nineteen brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $73.29.
Several equities analysts recently commented on INCY shares. Royal Bank of Canada increased their target price on shares of Incyte from $66.00 to $67.00 and gave the company a “sector perform” rating in a report on Thursday, August 15th. TD Cowen decreased their price objective on Incyte from $88.00 to $80.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Citigroup increased their target price on Incyte from $80.00 to $88.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Bank of America increased their price objective on Incyte from $62.00 to $66.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, StockNews.com downgraded shares of Incyte from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd.
Get Our Latest Research Report on INCY
Insider Transactions at Incyte
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Cape Investment Advisory Inc. purchased a new position in shares of Incyte in the 4th quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in Incyte in the second quarter worth about $26,000. Larson Financial Group LLC lifted its stake in shares of Incyte by 4,220.0% in the fourth quarter. Larson Financial Group LLC now owns 432 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 422 shares in the last quarter. Redmont Wealth Advisors LLC purchased a new stake in shares of Incyte during the first quarter valued at approximately $28,000. Finally, Riverview Trust Co bought a new stake in shares of Incyte during the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 96.97% of the company’s stock.
Incyte Trading Up 1.8 %
NASDAQ INCY opened at $64.38 on Friday. The stock’s 50-day simple moving average is $62.74 and its two-hundred day simple moving average is $58.90. Incyte has a twelve month low of $50.27 and a twelve month high of $70.36. The company has a quick ratio of 3.43, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $14.46 billion, a price-to-earnings ratio of 19.51, a PEG ratio of 1.14 and a beta of 0.73.
Incyte (NASDAQ:INCY – Get Free Report) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of $0.78 by ($2.60). Incyte had a return on equity of 0.75% and a net margin of 2.52%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the firm earned $0.77 EPS. The business’s quarterly revenue was up 9.3% compared to the same quarter last year. Research analysts forecast that Incyte will post 3.35 EPS for the current fiscal year.
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
See Also
- Five stocks we like better than Incyte
- Stock Dividend Cuts Happen Are You Ready?
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Insider Buying Explained: What Investors Need to Know
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Business Services Stocks Investing
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.